Akorn acquires eye drop solutions from Merck in $52.8M deal

Niche generic maker Akorn (AKRX +4.5%) rises after announcing the acquisition of the U.S. rights to AzaSite, COSOPT, COSOPT PF (they're all eye drop solutions) from Merck (MRK +0.3%) for $52.8M.

The move "further expands [our] position as a leader in U.S. ophthalmology products," AKRX CEO Raj Rai says.

For MRK, the deal is consistent with its "ongoing strategy to sharpen commercial focus and improve operational effectiveness." (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs